In accordance, Duffy et al. (2017) conducted a study and demonstrated the activation of the immune system following introduction checkpoint inhibitors and the accumulation of intratumoral CD8+ T-cells after RF ablation, thus establishing the synergism of the combined use of checkpoint inhibitor tremelimumab and ablation in the management of advanced hepatocellular carcinomas [90,91]. This evidence concerns the gene CD8A and hepatocellular carcinoma.